Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 GrowthGlobeNewsWire • 01/09/26
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)GlobeNewsWire • 12/04/25
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 11/04/25
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial ProgressGlobeNewsWire • 11/04/25
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of DirectorsGlobeNewsWire • 10/29/25
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025GlobeNewsWire • 10/21/25
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder ValuePRNewsWire • 08/15/25
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/08/25
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/08/25
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial ProgressPRNewsWire • 08/08/25
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity ProfilePRNewsWire • 08/08/25
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025PRNewsWire • 08/08/25
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025PRNewsWire • 07/29/25
Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 05/06/25
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate UpdatesPRNewsWire • 05/06/25
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent LitigationsPRNewsWire • 05/06/25
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/29/25
Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating OfficerPRNewsWire • 04/28/25